Ibrutinib Combination Therapies for Patients With CLL
Dec 19, 2023
A recent study examining the scientific rationale and clinical results of ibrutinib combinations in chronic lymphocytic leukemia (CLL) found that the combination of ibrutinib and targeted agent venetoclax may provide high complete response rates and, importantly, high rates of undetectable minimal residual disease (MRD; Blood Cancer J. 2021). Low complete remission rates, development of resistance, and uncommon substantial toxicities are some of the limitations of Ibrutinib as a treatment for CLL. Because Ibrutinib must be used until disease progression, it creates a financial burden on patients with CLL. “These limitations were the impetus for the development of ibrutinib combinations” wrote Natalia Timofeeva, Pre-clinical Cancer Researcher, University of Texas MD Anderson Cancer Center, and colleagues.
Radiation Oncologists Met With Congressional Leaders to Reverse CMS Cuts and Provide Equal Access to Care
Radiation oncologists met with Congress to urge leaders to consider how the Medicare and Medicaid Services (CMS) proposal to make significant cuts to radiation oncology facilities could be detrimental to the survival of patients with Read more…
FDA Approves Neoadjuvant Pembrolizumab Combination for Early TNBC Indication
The FDA granted approval to the supplemental biologics license application (sBLA) for pembrolizumab (Keytruda) as neoadjuvant therapy for patients with high-risk early-stage triple-negative breast cancer (TNBC) when given in combination with chemotherapy followed by single-agent Read more…
Recommended TVUS Screening Thresholds May Miss Endometrial Cancer in Black Women
Adherence to current clinical guidelines for the evaluation of postmenopausal bleeding may result in systematic underdiagnosis of endometrial cancer (EC) in Black women, according to a study published online July 15 in JAMA Oncology. Kemi M. Read more…